Talin 2 is a protein in humans that is encoded by the TLN2 gene. It belongs to the talin protein family.
This gene encodes a protein related to talin 1, a cytoskeletal protein that plays a significant role in the assembly of actin filaments. Talin-2 is expressed at high levels in cardiac muscle and functions to provide linkages between the extracellular matrix and actin cytoskeleton at costamere structures to transduce force laterally.[1]
Human talin-2 is 271.4 kDa and 2542 amino acids in length.[2] The size of talin-2 protein is similar to talin-1, and is relatively similar (74% identity, 86% similarity); the size of the talin-2 gene (200 kb) is however much larger than that of talin-1 (30 kb), due to differences in intron sizes.[3] Talin-2 mRNA is expressed in multiple tissues, including cardiac muscle, mouse embryonic stem cells, brain, lung, skeletal muscle, kidney and testis; however expression is highest in cardiac muscle.[3][4][5][6] A detailed analysis of the TLN2gene revealed that the alternative splicing of TLN2 is complex and encodes multiple mRNA transcripts and proteinisoforms. Studies revealed a promoter associated with a CpG island that accounts for most of the TLN2 expression in adult tissues. This promoter is separated from the first coding exon by approximately > 200 kb of alternatively spliced noncoding exons. The testis and kidney talin-2 isoforms lack the N-terminal 50% of the protein, and evidence suggests that this is the isoform expressed in elongating spermatids.[7] Talin is also post-translationally modified via calpain 2-mediated cleavage, which may target it for ubiquitin-proteasome-mediated degradation and turnover of associated cell adhesion structures.[8]
In patients with temporal lobe epilepsy, talin-2 protein was detected in cerebrospinal fluid, whereas expression was absent in non-epileptic patients.[16] Furthermore, postencephalitic epilepsy patients that were refractory to drug treatment exhibited markedly elevated levels of talin-2 protein in cerebrospinal fluid and reciprocally decreased levels in serum.[17] These data suggest that talin-2 may prove useful as a biomarker for epilepsy, and may be pathologically linked to this disease.
Studies have also shown that TLN2 is a direct target of miR-132, which is epigenetically silenced in prostate cancer,[18] suggesting that talin-2 may play a role in modulating cell adhesion in prostate cancer.
↑ 3.03.1Monkley SJ, Pritchard CA, Critchley DR (Sep 2001). "Analysis of the mammalian talin2 gene TLN2". Biochemical and Biophysical Research Communications. 286 (5): 880–5. doi:10.1006/bbrc.2001.5497. PMID11527381.
↑Chen NT, Lo SH (Nov 2005). "The N-terminal half of talin2 is sufficient for mouse development and survival". Biochemical and Biophysical Research Communications. 337 (2): 670–6. doi:10.1016/j.bbrc.2005.09.100. PMID16202389.
↑ 6.06.1Senetar MA, Moncman CL, McCann RO (Mar 2007). "Talin2 is induced during striated muscle differentiation and is targeted to stable adhesion complexes in mature muscle". Cell Motility and the Cytoskeleton. 64 (3): 157–73. doi:10.1002/cm.20173. PMID17183545.
↑Xiao F, Chen D, Lu Y, Xiao Z, Guan LF, Yuan J, Wang L, Xi ZQ, Wang XF (Feb 2009). "Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy". Brain Research. 1255: 180–9. doi:10.1016/j.brainres.2008.12.008. PMID19109932.
↑Xiao Z, Shen L, Chen D, Wang L, Xi Z, Xiao F, Wang X (Sep 2010). "Talin 2 concentrations in cerebrospinal fluid in patients with epilepsy". Clinical Biochemistry. 43 (13–14): 1129–32. doi:10.1016/j.clinbiochem.2010.06.015. PMID20620133.
↑Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, Levine AJ, Melino G, Bernardini S, Candi E (Jan 2013). "DNA methylation silences miR-132 in prostate cancer". Oncogene. 32 (1): 127–34. doi:10.1038/onc.2012.14. PMID22310291.
↑Hemmings L, Rees DJ, Ohanian V, Bolton SJ, Gilmore AP, Patel B, Priddle H, Trevithick JE, Hynes RO, Critchley DR (Nov 1996). "Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site". Journal of Cell Science. 109 (11): 2715–26. PMID8937989.
↑Patil S, Jedsadayanmata A, Wencel-Drake JD, Wang W, Knezevic I, Lam SC (Oct 1999). "Identification of a talin-binding site in the integrin beta(3) subunit distinct from the NPLY regulatory motif of post-ligand binding functions. The talin n-terminal head domain interacts with the membrane-proximal region of the beta(3) cytoplasmic tail". The Journal of Biological Chemistry. 274 (40): 28575–83. doi:10.1074/jbc.274.40.28575. PMID10497223.
↑Calderwood DA, Yan B, de Pereda JM, Alvarez BG, Fujioka Y, Liddington RC, Ginsberg MH (Jun 2002). "The phosphotyrosine binding-like domain of talin activates integrins". The Journal of Biological Chemistry. 277 (24): 21749–58. doi:10.1074/jbc.M111996200. PMID11932255.
↑Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH (Oct 1999). "The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation". The Journal of Biological Chemistry. 274 (40): 28071–4. doi:10.1074/jbc.274.40.28071. PMID10497155.
↑Wegener KL, Basran J, Bagshaw CR, Campbell ID, Roberts GC, Critchley DR, Barsukov IL (Sep 2008). "Structural basis for the interaction between the cytoplasmic domain of the hyaluronate receptor layilin and the talin F3 subdomain". Journal of Molecular Biology. 382 (1): 112–26. doi:10.1016/j.jmb.2008.06.087. PMID18638481.
↑Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL (Jul 1995). "Interaction of focal adhesion kinase with cytoskeletal protein talin". The Journal of Biological Chemistry. 270 (28): 16995–9. doi:10.1074/jbc.270.28.16995. PMID7622520.
↑Zheng C, Xing Z, Bian ZC, Guo C, Akbay A, Warner L, Guan JL (Jan 1998). "Differential regulation of Pyk2 and focal adhesion kinase (FAK). The C-terminal domain of FAK confers response to cell adhesion". The Journal of Biological Chemistry. 273 (4): 2384–9. doi:10.1074/jbc.273.4.2384. PMID9442086.
Shoeman RL, Hartig R, Hauses C, Traub P (2002). "Organization of focal adhesion plaques is disrupted by action of the HIV-1 protease". Cell Biology International. 26 (6): 529–39. doi:10.1006/cbir.2002.0895. PMID12119179.
Critchley DR, Holt MR, Barry ST, Priddle H, Hemmings L, Norman J (1999). "Integrin-mediated cell adhesion: the cytoskeletal connection". Biochemical Society Symposium. 65: 79–99. PMID10320934.
Di Paolo G, Pellegrini L, Letinic K, Cestra G, Zoncu R, Voronov S, Chang S, Guo J, Wenk MR, De Camilli P (Nov 2002). "Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin". Nature. 420 (6911): 85–9. doi:10.1038/nature01147. PMID12422219.
Ling K, Doughman RL, Firestone AJ, Bunce MW, Anderson RA (Nov 2002). "Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions". Nature. 420 (6911): 89–93. doi:10.1038/nature01082. PMID12422220.
Xiao F, Chen D, Lu Y, Xiao Z, Guan LF, Yuan J, Wang L, Xi ZQ, Wang XF (Feb 2009). "Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy". Brain Research. 1255: 180–9. doi:10.1016/j.brainres.2008.12.008. PMID19109932.
Critchley DR (Nov 2004). "Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion". Biochemical Society Transactions. 32 (Pt 5): 831–6. doi:10.1042/BST0320831. PMID15494027.
Vyas YM, Maniar H, Dupont B (Apr 2002). "Cutting edge: differential segregation of the SRC homology 2-containing protein tyrosine phosphatase-1 within the early NK cell immune synapse distinguishes noncytolytic from cytolytic interactions". Journal of Immunology. 168 (7): 3150–4. doi:10.4049/jimmunol.168.7.3150. PMID11907066.